Figure 6: Effect of Monoclonal Antibodies to IL-17A, IL-17F, or the IL-17RA Receptor Subunit on Glomerular Injury and Renal Fibrosis in Response to Ang II Infusion

(A) Glomerular injury was assessed by quantifying 24-h urinary excretion of albumin at baseline and after 14 or 28 days of Ang II infusion. Arrows indicate timing of antibody administration. Data are expressed as mean ± SEM and were analyzed at day 28 by 1-way analysis of variance followed by Holm-Sidak post hoc test (n = 7 to 15 per group). *p < 0.05; ***p < 0.001; ****p < 0.0001 vs. corresponding IgG1 control. (B) Renal fibrosis was assessed by quantifying transforming growth factor β1 (TGFβ1) from renal homogenates. Data from mice that received no antibodies and no Ang II (Untreated) are shown as a reference control. The other groups were infused with Ang II for 28 days and treated with the indicated antibodies twice weekly during the last 2 weeks of Ang II infusion. Data were analyzed by 1-way analysis of variance followed by Holm-Sidak post hoc test and expressed as mean ± SEM (n = 5 per group). *p < 0.05; ***p < 0.001; ****p < 0.0001. Abbreviations as in Figures 1, 2, and 3.